Home
/
Celldex Therapeutics, Inc.
/
Financials
/
Quarterly
Celldex Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Celldex Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2017
Sep 30, 2017
$3.92M
Nov 7, 2017
Q2
2017
Jun 30, 2017
$3.83M
Aug 8, 2017
Q1
2017
Mar 31, 2017
$1.53M
May 9, 2017
Q3
2016
Sep 30, 2016
$2.22M
Nov 7, 2016
Q2
2016
Jun 30, 2016
$1.39M
Aug 8, 2016
Q1
2016
Mar 31, 2016
$1.30M
May 5, 2016
Q3
2015
Sep 30, 2015
$1.03M
Nov 5, 2015
Q2
2015
Jun 30, 2015
$2.18M
Aug 10, 2015
Q1
2015
Mar 31, 2015
$486.0K
Apr 29, 2015
Q3
2014
Sep 30, 2014
$1.10M
Nov 5, 2014
Q2
2014
Jun 30, 2014
$592.0K
Aug 7, 2014
Q1
2014
Mar 31, 2014
$416.0K
May 1, 2014
Q3
2013
Sep 30, 2013
$980.0K
Nov 8, 2013
Q2
2013
Jun 30, 2013
$97.0K
Aug 6, 2013
Q1
2013
Mar 31, 2013
$2.41M
May 3, 2013
Q3
2012
Sep 30, 2012
$3.11M
Nov 2, 2012
Q2
2012
Jun 30, 2012
$2.01M
Aug 9, 2012
Q1
2012
Mar 31, 2012
$2.43M
May 4, 2012
Q3
2011
Sep 30, 2011
$2.36M
Nov 3, 2011
Q2
2011
Jun 30, 2011
$1.95M
Aug 4, 2011
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$1.42M
Nov 10, 2025
Q2
2025
Jun 30, 2025
$730.0K
Aug 7, 2025
Q1
2025
Mar 31, 2025
$695.0K
May 8, 2025
Q3
2025
Sep 30, 2024
$3.19M
Nov 10, 2025
Q2
2025
Jun 30, 2024
$2.50M
Aug 7, 2025
Q1
2025
Mar 31, 2024
$156.0K
May 8, 2025
Q3
2024
Sep 30, 2023
$1.52M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$268.0K
Aug 8, 2024
Q1
2024
Mar 31, 2023
$967.0K
May 6, 2024
Q3
2023
Sep 30, 2022
$407.0K
Nov 2, 2023
Q2
2023
Jun 30, 2022
$163.0K
Aug 8, 2023
Q1
2023
Mar 31, 2022
$174.0K
May 4, 2023
Q3
2022
Sep 30, 2021
$153.0K
Nov 9, 2022
Q2
2022
Jun 30, 2021
$3.48M
Aug 8, 2022
Q1
2022
Mar 31, 2021
$685.0K
May 5, 2022
Q3
2021
Sep 30, 2020
$668.0K
Nov 9, 2021
Q2
2021
Jun 30, 2020
$236.0K
Aug 5, 2021
Q1
2021
Mar 31, 2020
$2.73M
May 6, 2021
Q3
2020
Sep 30, 2019
$546.0K
Nov 5, 2020
Q2
2020
Jun 30, 2019
$715.0K
Aug 6, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($67.04M)
Nov 10, 2025
Q3
2025
Jun 30, 2025
($56.60M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($56.60M)
Aug 7, 2025
Q3
2025
Mar 31, 2025
($53.80M)
Nov 10, 2025
Q2
2025
Mar 31, 2025
($53.80M)
Aug 7, 2025
Q3
2025
Sep 30, 2024
($42.12M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($35.84M)
Aug 7, 2025
Q3
2025
Jun 30, 2024
($35.84M)
Nov 10, 2025
Q3
2025
Mar 31, 2024
($32.81M)
Nov 10, 2025
Q2
2025
Mar 31, 2024
($32.81M)
Aug 7, 2025
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($73.62M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($63.86M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($62.74M)
May 8, 2025
Q3
2025
Sep 30, 2024
($52.13M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($46.32M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($40.61M)
May 8, 2025
Q3
2024
Sep 30, 2023
($41.24M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($33.21M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($32.47M)
May 6, 2024
Q3
2023
Sep 30, 2022
($27.70M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($36.40M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($23.26M)
May 4, 2023
Q3
2022
Sep 30, 2021
($20.82M)
Nov 9, 2022
Q2
2022
Jun 30, 2021
($13.44M)
Aug 8, 2022
Q1
2022
Mar 31, 2021
($16.64M)
May 5, 2022
Q3
2021
Sep 30, 2020
($14.34M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($11.37M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($12.87M)
May 6, 2021
Q3
2020
Sep 30, 2019
($11.84M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($12.26M)
Aug 6, 2020